ScholarIQanswers from OpenAlex & ORCID
Jochen K. Lennerz
ResearcherPublications, citations & collaboration network
Jochen K. Lennerz is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jochen K. Lennerz have?
ScholarIQindexed works
Jochen K. Lennerz has 629 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jochen K. Lennerz have?
ScholarIQcitation count
Jochen K. Lennerz has 22,916 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jochen K. Lennerz?
ScholarIQh-index
Jochen K. Lennerz has an h-index of 74 in OpenAlex.
What is the i10-index of Jochen K. Lennerz?
ScholarIQi10-index
Jochen K. Lennerz has an i10-index of 224 in OpenAlex.
What is the ORCID of Jochen K. Lennerz?
ScholarIQorcid
The ORCID for Jochen K. Lennerz is on the source record.
What is the OpenAlex record for Jochen K. Lennerz?
ScholarIQopenalex
The OpenAlex for Jochen K. Lennerz is on the source record.
What are the most-cited papers on Jochen K. Lennerz?
ScholarIQmost cited works
A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells
Ken Cadwell, John Y. Liu, Sarah L. Brown, Hiroyuki Miyoshi, Joy Loh, Jochen K. Lennerz, Chieko Kishi, Wumesh KC, Javier A. Carrero, Steven R. Hunt, Christian D. Stone, Elizabeth M. Brunt, Ramnik J. Xavier, Barry P. Sleckman, Ellen Li, Noboru Mizushima, Thaddeus S. Stappenbeck, Herbert W. Virgin
A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity
Marina Cella, Anja Fuchs, William Vermi, Fabio Facchetti, Karel Otero, Jochen K. Lennerz, Jason M. Doherty, Jason C. Mills, Marco Colonna
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer
Justin F. Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo‐Jack, Shirish M. Gadgeel, Katherine R. Schultz, Manrose Singh, Emily Chin, Melissa Parks, Dana Lee, Richard H. DiCecca, Elizabeth L. Lockerman, Tiffany G. Huynh, Jennifer Logan, Lauren L. Ritterhouse, Long P. Le, Ashok Muniappan, Subba R. Digumarthy, Colleen L. Channick, Colleen Keyes, Gad Getz, Dora Dias‐Santagata, Rebecca S. Heist, Jochen K. Lennerz, Lecia V. Sequist, Cyril H. Benes, A. John Iafrate, Mari Mino–Kenudson, Jeffrey A. Engelman, Alice T. Shaw
COVID-19-neutralizing antibodies predict disease severity and survival
Wilfredo F. García-Beltrán, Evan C. Lam, Michael G. Astudillo, Diane Yang, Tyler E. Miller, Jared Feldman, Blake M. Hauser, Timothy M. Caradonna, Kiera Clayton, Adam D. Nitido, Mandakolathur R. Murali, Galit Alter, Richelle C. Charles, Anand S. Dighe, John A. Branda, Jochen K. Lennerz, Daniel Lingwood, Aaron G. Schmidt, A. John Iafrate, Alejandro B. Balazs
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Lipika Goyal, Supriya K. Saha, Leah Y. Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G. Ahronian, Jochen K. Lennerz, Phuong Vu, Vikram Deshpande, Avinash Kambadakone, Benedetta Mussolin, Stephanie Reyes, Laura E. Henderson, Jiaoyuan Elisabeth Sun, Emily E. Van Seventer, Joseph M. Gurski, Sabrina Baltschukat, Barbara Schacher-Engstler, Louise Barys, Christelle Stamm, Pascal Furet, David P. Ryan, James R. Stone, A. John Iafrate, Gad Getz, Diana Graus Porta, Ralph Tiedt, Alberto Bardelli, Dejan Juric, Ryan B. Corcoran, Nabeel Bardeesy, Andrew X. Zhu